Stitched peptides as potential cell permeable inhibitors of oncogenic DAXX protein

Clare Jelinska1,2,3, Srinivasaraghavan Kannan4, Yuri Frosi5

  • 1NTU Institute of Structural Biology, Experimental Medicine Building Level 06-01, 59 Nanyang Drive 636921 Singapore csiclar@nus.edu.sg.

RSC Chemical Biology
|November 30, 2023
PubMed

Insights

Researchers developed novel stitched peptides targeting DAXX (Death Domain Associated Protein 6), a protein upregulated in cancers. These peptides inhibit DAXX, disrupt cancer progression, and show therapeutic potential.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • DAXX (Death Domain Associated Protein 6) is upregulated in cancers, contributing to tumor progression.
  • DAXX plays roles in chromatin remodeling, transcription regulation, and DNA repair.
  • DAXX is a potential therapeutic target due to its role in cancer.

Purpose of the Study:

  • To design and develop novel stapled/stitched peptides targeting the DAXX N-terminal helical bundle domain.
  • To investigate the binding affinity and inhibitory effects of these peptides on DAXX.
  • To assess the cell permeability and stability of the developed peptides.

Main Methods:

  • Structure-based design of stapled/stitched peptides.
  • Biochemical assays to measure peptide binding affinity and DAXX inhibition.
  • Cellular assays to evaluate peptide uptake, intracellular concentration, and membrane effects.

Main Results:

  • Novel peptides were designed to specifically target DAXX.
  • The peptides exhibit high affinity for DAXX, exceeding that of known interaction partners.
  • Peptides successfully inhibit DAXX, release its auto-inhibited SIM, and facilitate SUMO-1 interaction.
  • Stitched peptides demonstrate efficient cell entry and sustained intracellular nanomolar concentrations without membrane perturbation.

Conclusions:

  • Developed stitched peptides are effective DAXX inhibitors.
  • These peptides serve as valuable tools for studying DAXX molecular interactions.
  • The peptides show promise as a basis for developing new cancer therapeutics.